156 related articles for article (PubMed ID: 23662843)
1. Fabry disease: is there a role for enzyme replacement therapy?
Mehta AB
J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
[No Abstract] [Full Text] [Related]
2. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
[TBL] [Abstract][Full Text] [Related]
3. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: dose matters.
Warnock DG; Mauer M
J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
[No Abstract] [Full Text] [Related]
5. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
Martin-Suárez I; Suárez-Marrero C
Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
[No Abstract] [Full Text] [Related]
6. Stroke and Chronic Kidney Disease in Fabry Disease.
Tapia D; Kimonis V
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy for Fabry's disease.
Waldek S; Germain DP; Wanner C; Warnock DG
Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
[No Abstract] [Full Text] [Related]
8. Diagnosis and management of kidney involvement in Fabry disease.
Warnock DG; West ML
Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy for Fabry's disease.
Deegan P
Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
[No Abstract] [Full Text] [Related]
10. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
11. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
12. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
[No Abstract] [Full Text] [Related]
13. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
[No Abstract] [Full Text] [Related]
14. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
15. Undiagnosed Fabry disease: the importance of screening for Fabry disease before transcutaneous patent foramen ovale closure in a young patient with cryptogenic stroke.
Chimenti C; Alfarano M; Galea N; Verardo R; Grande C; Frustaci A
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):711-713. PubMed ID: 32251074
[No Abstract] [Full Text] [Related]
16. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
17. Enzyme replacement in Fabry disease: the essence is in the kidney.
Schiffmann R
Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
[No Abstract] [Full Text] [Related]
18. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
19. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
Linthorst GE; Aerts JM
J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
[No Abstract] [Full Text] [Related]
20. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
